Skip to main content

Advertisement

SpringerLink
Log in

Dendritic cell-based cancer immunotherapies

  • Review
  • Published:
Archivum Immunologiae et Therapiae Experimentalis Aims and scope

Abstract

Because of their unique role in linking the innate and adaptive immune systems, dendritic cells (DCs) have been a logical focus for novel immunotherapies. However, strategies employing active immunization with ex vivo generated and antigen–pulsed DCs have shown limited efficacy in clinical trials. These past approaches did not take into account the complex interactions between cells of the innate immune system and DCs during DC maturation, antigen processing, and presentation to naïve T cells. By better understanding the natural sequence of events occurring in vivo during an effective immune response, we can tailor antitumor immunotherapeutic strategies to augment aspects of this response from the activation of innate immune cells to antigen uptake and DC maturation to priming of naïve T cells and, ultimately, to the establishment of antitumor immunity. Current DC vaccination strategies utilize a number of methods to recapitulate the cascade of events that culminate in a protective antitumor immune response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adams S, O’Neill DW, Nonaka D et al (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181: 776–784

    PubMed  CAS  Google Scholar 

  • Ahonen CL, Doxsee CL, McGurran SM et al (2004) Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199: 775–784

    Article  PubMed  CAS  Google Scholar 

  • Antonia S, Mule JJ, Weber JS (2004) Current developments of immunotherapy in the clinic. Curr Opin Immunol 16: 130–136

    Article  PubMed  CAS  Google Scholar 

  • Asea A, Kraeft SK, Kurt-Jones EA et al (2000) HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6: 435–442

    Article  PubMed  CAS  Google Scholar 

  • Aspord C, Pedroza-Gonzalez A, Gallegos M et al (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204: 1037–1047

    Article  PubMed  CAS  Google Scholar 

  • Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296–306

    Article  PubMed  CAS  Google Scholar 

  • Basu S, Binder RJ, Ramalingam T et al (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14: 303–313

    Article  PubMed  CAS  Google Scholar 

  • Basu S, Binder R, Suto R et al (2000) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF- B pathway. Int Immunol 12: 1539–1546

    Article  PubMed  CAS  Google Scholar 

  • Berzofsky JA, Terabe M (2008) NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 180: 3627–3635

    PubMed  CAS  Google Scholar 

  • Beutner KR, Geisse JK, Helman D et al (1999) Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41: 1002–1007

    Article  PubMed  CAS  Google Scholar 

  • Bezbradica JS, Stanic AK, Matsuki N et al (2005) Distinct roles of dendritic cells and B cells in Vα14Jα18 natural T cell activation in vivo. J Immunol 174:4 696–705

    Google Scholar 

  • Binder RJ, Vatner R, Srivastava P (2004) The heat-shock protein receptors: some answers and more questions. Tissue Antigens 64: 442–441

    Article  PubMed  CAS  Google Scholar 

  • Butowski N, Lamborn KR, Lee BL et al (2009) A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 91: 183–189

    Article  PubMed  CAS  Google Scholar 

  • Chang DH, Osman K, Connolly J et al (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503–1517

    Article  PubMed  CAS  Google Scholar 

  • Chomarat P, Dantin C, Bennett L et al (2003) TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 171: 2262–2269

    PubMed  CAS  Google Scholar 

  • Creagh EM, O’Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27: 352–357

    Article  PubMed  CAS  Google Scholar 

  • Curiel TJ (2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol 20: 241–246

    Article  PubMed  CAS  Google Scholar 

  • Datta SK, Cho HJ, Takabayashi K et al (2004) Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications. Immunol Rev 199: 217–226

    Article  PubMed  CAS  Google Scholar 

  • Davis ID, Jefford M, Parente P et al (2003) Rational approaches to human cancer immunotherapy. J Leukoc Biol 73: 3–29

    Article  PubMed  CAS  Google Scholar 

  • Delano MJ, Scumpia PO, Weinstein JS et al (2007) MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 204: 1463–1474

    Article  PubMed  CAS  Google Scholar 

  • Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophate colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539–3543

    Article  PubMed  CAS  Google Scholar 

  • Endharti AT, Rifa’I M, Shi Z et al (2005) Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol 175: 7093–7097

    PubMed  CAS  Google Scholar 

  • Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3: 630–641

    Article  PubMed  CAS  Google Scholar 

  • Fujii S, Fujimoto K, Shimizu K et al (1999) Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res 59: 2150–2158

    PubMed  CAS  Google Scholar 

  • Fujii S, Shimizu K, Hemmi H et al (2007) Innate Va14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 220: 183–198

    Article  PubMed  CAS  Google Scholar 

  • Fujii S, Shimizu K, Kronenberg M et al (2002) Prolonged interferon-γ producing NKT response induced with α-galactosylceramide-loaded dendritic cells. Nat Immunol 3: 867–874

    Article  PubMed  CAS  Google Scholar 

  • Gehrmann M, Schmetzer H, Eissner G et al (2003) Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells. Haematologica 88: 474–476

    PubMed  Google Scholar 

  • Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117: 1195–1203

    Article  PubMed  CAS  Google Scholar 

  • Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199: 251–263

    Article  PubMed  CAS  Google Scholar 

  • Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111–135

    Article  PubMed  CAS  Google Scholar 

  • Hege KM, Jooss K, Pardoll D (2006) GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol 25: 321–352

    Article  PubMed  CAS  Google Scholar 

  • Heiser A, Coleman D, Dannull J et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409–417

    PubMed  CAS  Google Scholar 

  • Heiser A, Dahm P, Yancey D et al (2000) Human dendritic cells transfected with RNA encoding prostate specific antigen (PSA) stimulate prostate specific CTL responses in vitro. J Immunol 164: 5508–5514

    PubMed  CAS  Google Scholar 

  • Heiser A, Maurice MA, Yancey DR et al (2001) Induction of polyclonal prostate cancer-specific ctl using dendritic cells transfected with amplified tumor rna. J Immunol 166: 2953–2960

    PubMed  CAS  Google Scholar 

  • Heit A, Schmitz F, O’Keeffe M et al (2005) Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 174: 4373–4380

    PubMed  CAS  Google Scholar 

  • Higano CS, Corman JM, Smith DC et al (2008) Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113: 975–984

    Article  PubMed  CAS  Google Scholar 

  • Huang B, Pan PY, Li Q et al (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123–1131

    Article  PubMed  CAS  Google Scholar 

  • Inaba K, Inaba M, Romani N et al (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693–1702

    Article  PubMed  CAS  Google Scholar 

  • Ishikawa A, Motohashi S, Ishikawa E et al (2005) A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910–1917

    Article  PubMed  CAS  Google Scholar 

  • Jaffee EM, Abrams R, Cameron J et al (1998) A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 9: 1951–1971

    Article  PubMed  CAS  Google Scholar 

  • Jaffee EM, Hruban RH, Biedrzycki B et al (2001) Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19: 145–156

    PubMed  CAS  Google Scholar 

  • Jonuleit H, Kuhn U, Muller G et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27: 3135–3142

    Article  PubMed  CAS  Google Scholar 

  • Larmonier N, Marron M, Zeng Y et al (2007) Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol Immunother 56: 48–59

    Article  PubMed  CAS  Google Scholar 

  • Larmonier N, Merino D, Nicolas A et al (2006) Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 11: 1513–1524

    Article  PubMed  CAS  Google Scholar 

  • Lewis JJ (2004) Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci USA 101(suppl 2): 14653–14656

    Article  PubMed  CAS  Google Scholar 

  • Luft T, Pang KC, Thomas E et al (1998) Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161: 1947–1953

    PubMed  CAS  Google Scholar 

  • Manegold C, Gravenor D, Woytowitz D et al (2008) Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3979–3986

    Article  PubMed  CAS  Google Scholar 

  • Marigo I, Dolcetti L, Serafini P et al (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222: 162–179

    Article  PubMed  CAS  Google Scholar 

  • Mazzaferro V, Coppa J, Carrabba M et al (2003) Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9: 3235–3245

    PubMed  CAS  Google Scholar 

  • Melcher A, Gough M, Todryk S et al (1999) Apoptosis or necrosis for tumor immunotherapy: what’s in a name?. J Mol Med 77: 824–833

    Article  PubMed  CAS  Google Scholar 

  • Misra N, Bayry J, Lacroix-Desmazes S et al (2004) Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172: 4676–4680

    PubMed  CAS  Google Scholar 

  • Mohamadzadeh M, Berard F, Essert G et al (2001) Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 194: 1013–1020

    Article  PubMed  CAS  Google Scholar 

  • Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68: 2561–2563

    Article  PubMed  CAS  Google Scholar 

  • Nagaraj S, Gupta K, Pisarev V et al (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13: 828–835

    Article  PubMed  CAS  Google Scholar 

  • Nair SK, Boczkowski D, Morse M et al (1998) Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16: 364–369

    Article  PubMed  CAS  Google Scholar 

  • Nair SK, Heiser A, Boczkowski D et al (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6: 1011–1017

    Article  PubMed  CAS  Google Scholar 

  • Nemunaitis J, Jahan T, Ross H et al (2006) Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 13: 555–562

    Article  PubMed  CAS  Google Scholar 

  • Nieda M, Okai M, Tazbirkova A et al (2004) Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383–389

    Article  PubMed  CAS  Google Scholar 

  • Palucka AK, Ueno H, Connolly J et al (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29: 545–557

    Article  PubMed  CAS  Google Scholar 

  • Paquette RL, Hsu NC, Kiertscher SM et al (1998) Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 64: 358–367

    PubMed  CAS  Google Scholar 

  • Parekh VV, Wilson MT, Olivares-Villagomez D et al (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115: 2572–2583

    Article  PubMed  CAS  Google Scholar 

  • Parkhurst MR, Salgaller ML, Southwood S et al (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157: 2539–2548

    PubMed  CAS  Google Scholar 

  • Prasad SJ, Farrand KJ, Matthews SA et al (2005) Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 174: 90–98

    PubMed  CAS  Google Scholar 

  • Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T helper and a T-killer cell. Nature 393: 474–478

    Article  PubMed  CAS  Google Scholar 

  • Rifa’i M, Kawamoto Y, Nakashima I et al (2004) Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 200: 1123–1134

    Article  PubMed  CAS  Google Scholar 

  • Romani N, Gruner S, Brang D et al (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83–93

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909–915

    Article  PubMed  CAS  Google Scholar 

  • Salgaller ML, Marincola FM, Cormier JN et al (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56: 4749–4757

    PubMed  CAS  Google Scholar 

  • Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Exp Med 179: 1109–1118

    Article  CAS  Google Scholar 

  • Sanchez PJ, McWilliams JA, Haluszczak C et al (2007) Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol 178: 1564–1572

    PubMed  CAS  Google Scholar 

  • Santini SM, Lapenta C, Logozzi M et al (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191: 1777–1788

    Article  PubMed  CAS  Google Scholar 

  • Sauter B, Albert ML, Francisco L et al (2000) Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423–434

    CAS  Google Scholar 

  • Schmitt E, Gehrmann M, Brunet M et al (2007) Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81: 15–27

    Article  PubMed  CAS  Google Scholar 

  • Schnurr M, Scholz C, Rothenfusser S et al (2002) Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK γδ and d T cells. Cancer Res. 62: 2347–2352

    PubMed  CAS  Google Scholar 

  • Schoenberger SP, Toes RE, van der Voort EI et al (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480–483

    Article  PubMed  CAS  Google Scholar 

  • Serafini P, Mgebroff S, Noonan K et al (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68: 5439–5449

    Article  PubMed  CAS  Google Scholar 

  • Shimizu K, Goto A, Fukui M et al (2007) Tumor cells loaded with α-galactosylceramide Induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 178: 2853–2861

    PubMed  CAS  Google Scholar 

  • Shimizu K, Kurosawa Y, Taniguchi M et al (2007) Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 204: 2641–2653

    Article  PubMed  CAS  Google Scholar 

  • Silk JD, Salio M, Reddy BG et al (2008) Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol 180: 6452–6456

    PubMed  CAS  Google Scholar 

  • Simons JW, Carducci MA, Mikhak B et al (2006) Phase I/II trial of an allogeneic cellular immunotherapy in hormonenaive prostate cancer. Clin Cancer Res 12: 3394–3401

    Article  PubMed  CAS  Google Scholar 

  • Simons JW, Jaffee EM, Weber CE et al (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537–1546

    PubMed  CAS  Google Scholar 

  • Small EJ, Sacks N, Nemunaitis J et al (2007) Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13: 3883–3891

    Article  PubMed  CAS  Google Scholar 

  • Soiffer R, Lynch T, Mihm M et al (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95: 13141–13146

    Article  PubMed  CAS  Google Scholar 

  • Solinger AM, Ultee ME, Margoliash E et al (1979) T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. J Exp Med 150: 830–848

    Article  PubMed  CAS  Google Scholar 

  • Solit AB, Osman I, Polsky D et al (2008) Phase II trial of 17–allyamino-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302–8307

    Article  PubMed  CAS  Google Scholar 

  • Srivastava P (2002a) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2: 185–194

    Article  PubMed  CAS  Google Scholar 

  • Srivastava P (2002b) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395–425

    Article  PubMed  CAS  Google Scholar 

  • Stuge TB, Holmes SP, Saharan S et al (2004) Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 1: e28 Su Z, Dannull J, Yang BK et al–2005 Telomerase mRNA transfected dendritic cells stimulate antigenspecific CD8 and CD4 T cell responses in patients with metastatic prostate cancer J Immunol 17437983807

    Article  CAS  Google Scholar 

  • Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018–1028

    Article  PubMed  CAS  Google Scholar 

  • Tacken PJ, de Vries IJ, Torensma R et al (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7: 790–802

    Article  PubMed  CAS  Google Scholar 

  • Terabe M, Berzofsky JA (2007) NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 28: 491–496

    Article  PubMed  CAS  Google Scholar 

  • Testori A, Richards J, Whitman E et al (2008) Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 26: 955–962

    Article  PubMed  CAS  Google Scholar 

  • Todryk SM, Melcher AA, Dalgleish AG et al (2000) Heat shock proteins refine the danger theory. Immunology 99: 334–337

    Article  PubMed  CAS  Google Scholar 

  • Urba WJ, Nemunaitis J, Marshall F et al (2008) Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 180: 2011–2018

    Article  PubMed  CAS  Google Scholar 

  • van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27: 49–55

    Article  PubMed  CAS  Google Scholar 

  • Vonderheide RH, Flaherty KT, Khalil M et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25: 876–883

    Article  PubMed  CAS  Google Scholar 

  • Wang Y, Kelly CG, Singh M et al (2002) Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J Immunol 169: 2422–2429

    PubMed  CAS  Google Scholar 

  • Wille-Reece U, Flynn BJ, Lore K et al (2005) HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 102: 15190–15194

    Article  PubMed  CAS  Google Scholar 

  • Yarovinsky F, Kanzler H, Hieny S et al (2006) Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity 25: 655–664

    Article  PubMed  CAS  Google Scholar 

  • Wood C, Srivastava P, Bukowski R et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicenter, open-label, randomised phase III trial. Lancet 372: 145–154

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Unit for Cellular Immunotherapy, Research Center for Allergy and Immunology (RCAI), Institute of Physical and Chemical Research (RIKEN), Yokohama RIKEN, 1-7-22, Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan

    Shin-ichiro Fujii (MD Ph.D.), Miki Asakura, Kaori Aki & Kanako Shimizu

  2. Division of Cancer Genomics, Cancer Institute (Japanese Foundation for Cancer Research), Koto-ku, Tokyo, Japan

    Takuya Takayama

  3. NTT West Kyushu Hospital, Kumamoto, Kumamoto, Japan

    Koji Fujimoto

  4. Research Unit for Therapeutic Model, Research Center for Allergy and Immunology (RCAI), Institute of Physical and Chemical Research (RIKEN), Yokohama, Kanagawa, Japan

    Kanako Shimizu

Authors
  1. Shin-ichiro Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takuya Takayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miki Asakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kaori Aki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koji Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kanako Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shin-ichiro Fujii.

About this article

Cite this article

Fujii, Si., Takayama, T., Asakura, M. et al. Dendritic cell-based cancer immunotherapies. Arch. Immunol. Ther. Exp. 57, 189–198 (2009). https://doi.org/10.1007/s00005-009-0025-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00005-009-0025-x

Keywords

Search

Navigation